CHOC Children's is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Mark Daniels, MD, the TrialNet team at CHOC Children's is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Dr. Mark Daniels has served as Principal Investigator for the TrialNet studies conducted here at CHOC. He has been board certified in pediatric endocrinology since 2003 after completing his medical school training, residency and pediatric endocrinology fellowship at Stanford University
Timothy K. Flannery, M.D., is Board Certified in Pediatrics and in Pediatric Endocrinology who treats kids and teens in Orange County. Dr. Flannery attended medical school at Oral Roberts University School of Medicine in Tulsa, Oklahoma. He served his internship and residency in Pediatrics at Loma Linda University Medical Center in California, followed by his residency in Pediatric Endocrinology at Baylor College of Medicine in Houston, Texas. He has special interest in growth disorders, pituitary and calcium disorders.
Himala Kashmiri M.D., is a board-certified pediatric endocrinologist since 2013 who treats the full spectrum of endocrinology disorders in kids in Orange County. He received his medical school training at the University of Health Science Center at North Texas and completed his residency at Loyola University (Chicago, IL). During his fellowship research training at Children’s Hospital of Wisconsin (Milwaukee, WI), he worked with Hessner’s lab on the unique transcription profile signatures in type 1 diabetes patients and other autoimmune diseases. In 2015, he moved back to Southern California to work at CHOC hospital and works closely as a co-investigator with our research team on TrialNet studies. Dr. Kashmiri is a valuable provider as he is able to communicate with our Hispanic/Latino patient community in Spanish.
Amrit Bhangoo M.D., is a pediatric endocrinologist with a decade of experience teaching medical students, pediatric residents, pediatric endocrinology and adult endocrinology fellows. Dr. Bhangoo is board certified in both General Pediatrics and in Pediatric Endocrinology. Dr. Bhangoo is currently serving as the Director of Research at CHOC Children’s Endocrinology Division. He is also an attending physician at CHOC Children’s and Assistant Professor of Pediatrics, University of California Irvine. Dr. Bhangoo earned his medical degree from India. In the United States he underwent fellowship and residency training at Maimonides Children’s Hospital of Brooklyn, New York. He worked as an attending physician at SUNY Downstate Medical Center, New York before moving to California.
Dr. Bhangoo is an author of a medical textbook with the title ‘Noonan Syndrome: Characteristics and Interventions’, which was published in 2019 and has 40 peer reviewed publications. He has served as a senior editor of Endocrinology, Diabetes & Metabolism Case Reports and has served on editorial boards of Journal of Pediatric Endocrinology and Endocrinology and Metabolic Research. He has also served as a reviewer on multiple journals including Pediatrics, Clinical Endocrinology, JCEM, Endocrine, and the European Journal of Endocrinology. He has contributed book chapters to the Textbook of Pediatric Endocrinology, Pediatric Adrenal Diseases and Genetic Steroid Disorders. Dr. Bhangoo also has served the pediatric endocrine community at the national level. He has served on the Pediatric Endocrine Society Drug & Therapeutics Subcommittee from 2016- 2018. He continues as a board member of a non-profit Human Growth Foundation. Dr. Bhangoo has successfully organized 2 educational endocrine symposia at CHOC with full day of CME activities. Both symposiums were well attended by various community healthcare providers.
Lien Trinh, M.D., is Board Certified in Pediatrics and in Pediatric Endocrinology. She is an attending physician at CHOC Children’s and Assistant Professor of Pediatrics, University of California Irvine. Prior to joining CHOC Children’s, Dr. Trinh attended medical school in Grenada at St. George’s University, School of Medicine. She served her internship and residency at St. Vincent’s Catholic Medical Center, New York Medical College and completed her fellowship training in Pediatrics Endocrinology at Mount Sinai School of Medicine in New York. Dr. Trinh treats all endocrine disorders, she has special interest in adrenal disorders, growth, puberty and management of diabetes mellitus. Dr. Trinh is fluent in Vietnamese.
Sarah Hu is a pediatric nurse practitioner who specializes in the management of infants, children and teens with endocrine conditions at CHOC Children's in Orange County.
Francoise Sutton is a nurse practitioner who specializes in the care of endocrinology disorders in kids at CHOC Children's in Orange County.
Marissa Erickson MPH CRC has been an active and effective research coordinator in the Diabetes TrialNet Study. She has recruited study subjects for the Pathway to Prevention Screening study. She is a skilled phlebotomist and has excellent rapport with our CHOC Diabetes Families, local Orange County diabetes support groups, health care personnel, and outreach fairs. Her Spanish language proficiency has been a valuable source in assisting Hispanic families.
Heather Speer CCRC MPH CHES CDE has been a very active and effective research coordinator in the Diabetes Prevention Trial-Type 1 and TrialNet. She is dedicated to recruiting study subjects for all the studies through excellent networking relationships with the TrialNet personnel and local physicians, support groups, health care personnel, and outreach community fairs.
If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More
Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More
We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D. Details
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 or stage 2), and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression. Details
If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More